Q2 2024 EPS Estimates for Krystal Biotech, Inc. (NASDAQ:KRYS) Lifted by HC Wainwright

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for Krystal Biotech in a research note issued on Monday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will earn $0.37 per share for the quarter, up from their previous estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $1.82 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2024 earnings at $0.31 EPS, Q4 2024 earnings at $0.18 EPS and FY2024 earnings at $0.89 EPS.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million during the quarter, compared to analyst estimates of $47.37 million. The company’s revenue was up 452400.0% on a year-over-year basis. During the same period last year, the business posted ($1.76) EPS.

Several other analysts also recently weighed in on KRYS. Guggenheim lifted their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Citigroup increased their price target on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, William Blair restated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $171.00.

Krystal Biotech Price Performance

Shares of KRYS opened at $158.74 on Wednesday. The firm has a market capitalization of $4.53 billion, a price-to-earnings ratio of 84.89 and a beta of 0.91. Krystal Biotech has a 1-year low of $86.03 and a 1-year high of $189.97. The company has a 50-day moving average of $168.75 and a 200 day moving average of $134.44.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the transaction, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The disclosure for this sale can be found here. Insiders sold 38,087 shares of company stock valued at $6,210,591 over the last 90 days. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of KRYS. Vanguard Group Inc. grew its position in Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after purchasing an additional 35,632 shares during the last quarter. Jennison Associates LLC increased its position in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after acquiring an additional 383,495 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Krystal Biotech by 5.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after acquiring an additional 30,169 shares during the period. TimesSquare Capital Management LLC raised its stake in Krystal Biotech by 103.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock worth $31,073,000 after acquiring an additional 127,435 shares during the last quarter. Finally, First Turn Management LLC acquired a new stake in Krystal Biotech during the 4th quarter worth about $30,045,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).